Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B RAMOT

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
Cancer|December 1, 1975
Childhood Hodgkin's disease in Israel. A study of 17 casesE Aghai, H Brenner, B Ramot
Blood|February 1, 1976
Preleukemia and leukemia in polycythemia veraD Meytes, D Katz, B Ramot
Clinical and Experimental Immunology|September 1, 1987
Normal natural killer cell activity in Hodgkin's disease patients in remissionD Douer, N Shaked, B Ramot
Acta Haematologica|March 1, 1977
Peripheral blood lymphocytes in systemic lupus erythematosus. Relation to activityR Michalevicz, A Many, B Ramot
Israel Journal of Medical Sciences|June 1, 1976
Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemicD Meytes, D Katz, B Ramot
Cancer|April 1, 1981
Chronic lymphatic leukemia terminating in acute myeloid leukemia: review of the literatureN Stern, J Shemesh, B Ramot
European Journal of Haematology|August 1, 1990
Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusionsI Ben-Bassat, D Douer, B Ramot
Israel Journal of Medical Sciences|April 1, 1985
Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serumD Douer, E Schwartz, N Shaked, et al.
Blood|April 1, 1985
Production of burst-promoting activity by monoclonal antibody defined malignant T lymphocytes from patients with lymphocytic leukemia and lymphomaP Froom, B Ramot, M Biniaminov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1987
Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicityY Kaufmann, M Levanon, J Davidsohn, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
Cancer|December 1, 1975
Childhood Hodgkin's disease in Israel. A study of 17 casesE Aghai, H Brenner, B Ramot
Blood|February 1, 1976
Preleukemia and leukemia in polycythemia veraD Meytes, D Katz, B Ramot
Clinical and Experimental Immunology|September 1, 1987
Normal natural killer cell activity in Hodgkin's disease patients in remissionD Douer, N Shaked, B Ramot
Acta Haematologica|March 1, 1977
Peripheral blood lymphocytes in systemic lupus erythematosus. Relation to activityR Michalevicz, A Many, B Ramot
Israel Journal of Medical Sciences|June 1, 1976
Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemicD Meytes, D Katz, B Ramot
Cancer|April 1, 1981
Chronic lymphatic leukemia terminating in acute myeloid leukemia: review of the literatureN Stern, J Shemesh, B Ramot
European Journal of Haematology|August 1, 1990
Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusionsI Ben-Bassat, D Douer, B Ramot
Israel Journal of Medical Sciences|April 1, 1985
Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serumD Douer, E Schwartz, N Shaked, et al.
Blood|April 1, 1985
Production of burst-promoting activity by monoclonal antibody defined malignant T lymphocytes from patients with lymphocytic leukemia and lymphomaP Froom, B Ramot, M Biniaminov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1987
Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicityY Kaufmann, M Levanon, J Davidsohn, et al.
Pageof 12